{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:26:59Z","timestamp":1793676419836,"version":"4.5.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09364-y","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:19:00Z","timestamp":1788844740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cross-disease protein aggregate interactions in neurodegeneration: from molecular mechanisms to therapeutic strategies"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6716-5130","authenticated-orcid":false,"given":"Wenqi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5732-3806","authenticated-orcid":false,"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"9364_CR1","unstructured":"GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105-e125."},{"issue":"1","key":"9364_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14(1):32","journal-title":"Mol Neurodegener"},{"issue":"3","key":"9364_CR3","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2666-7568(23)00019-3","volume":"4","author":"E Nichols","year":"2023","unstructured":"Nichols E, Merrick R, Hay SI et al (2023) The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. Lancet Healthy Longev 4(3):e115\u2013e125","journal-title":"Lancet Healthy Longev"},{"issue":"6","key":"9364_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27061776","volume":"27","author":"S Subedi","year":"2022","unstructured":"Subedi S, Sasidharan S, Nag N, Saudagar P, Tripathi T (2022) Amyloid cross-seeding: mechanism, implication, and inhibition. Molecules 27(6):1776","journal-title":"Molecules"},{"issue":"7","key":"9364_CR5","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/brain\/awab092","volume":"144","author":"PA Boyle","year":"2021","unstructured":"Boyle PA, Wang T, Yu L et al (2021) To what degree is late life cognitive decline driven by age-related neuropathologies? Brain 144(7):2166\u20132175","journal-title":"Brain"},{"issue":"1","key":"9364_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00391-7","volume":"15","author":"T Guo","year":"2020","unstructured":"Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer\u2019s disease. Mol Neurodegener 15(1):40","journal-title":"Mol Neurodegener"},{"issue":"10","key":"9364_CR7","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT (2020) Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci 23(10):1183\u20131193","journal-title":"Nat Neurosci"},{"issue":"6577","key":"9364_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1126\/science.abm7285","volume":"375","author":"Y Yang","year":"2022","unstructured":"Yang Y, Arseni D, Zhang W et al (2022) Cryo-EM structures of amyloid-\u03b2 42 filaments from human brains. Science 375(6577):167\u2013172","journal-title":"Science"},{"issue":"147","key":"9364_CR9","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff JJ, Wang M, Liao Y et al (2012) A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci Transl Med 4(147):147ra111","journal-title":"Sci Transl Med"},{"issue":"4","key":"9364_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.4103\/1673-5374.382231","volume":"19","author":"M Jin","year":"2024","unstructured":"Jin M, Wang S, Gao X, Zou Z, Hirotsune S, Sun L (2024) Pathological and physiological functional cross-talks of \u03b1-synuclein and tau in the central nervous system. Neural Regen Res 19(4):855\u2013862","journal-title":"Neural Regen Res"},{"issue":"23","key":"9364_CR11","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.2174\/092986708785909111","volume":"15","author":"CX Gong","year":"2008","unstructured":"Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. Curr Med Chem 15(23):2321\u20132328","journal-title":"Curr Med Chem"},{"issue":"4","key":"9364_CR12","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259","journal-title":"Acta Neuropathol"},{"issue":"1","key":"9364_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00401-019-02087-9","volume":"139","author":"M Colin","year":"2020","unstructured":"Colin M, Dujardin S, Schraen-Maschke S et al (2020) From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. Acta Neuropathol 139(1):3\u201325","journal-title":"Acta Neuropathol"},{"issue":"6645","key":"9364_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(6645):839\u2013840","journal-title":"Nature"},{"issue":"3","key":"9364_CR15","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1750-3639.2000.tb00269.x","volume":"10","author":"RL Hamilton","year":"2000","unstructured":"Hamilton RL (2000) Lewy bodies in Alzheimer\u2019s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 10(3):378\u2013384","journal-title":"Brain Pathol"},{"issue":"1","key":"9364_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","volume":"16","author":"DJ Irwin","year":"2017","unstructured":"Irwin DJ, Grossman M, Weintraub D et al (2017) Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 16(1):55\u201365","journal-title":"Lancet Neurol"},{"issue":"5619","key":"9364_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1126\/science.1082324","volume":"300","author":"BI Giasson","year":"2003","unstructured":"Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, Trojanowski JQ, Lee VM-Y (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619):636\u2013640","journal-title":"Science"},{"issue":"1","key":"9364_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-025-00822-3","volume":"20","author":"N Franzmeier","year":"2025","unstructured":"Franzmeier N, Roemer-Cassiano SN, Bernhardt AM et al (2025) Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer\u2019s disease. Mol Neurodegener 20(1):31","journal-title":"Mol Neurodegener"},{"issue":"5796","key":"9364_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1126\/science.1134108","volume":"314","author":"M Neumann","year":"2006","unstructured":"Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314(5796):130\u2013133","journal-title":"Science"},{"issue":"3","key":"9364_CR20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00401-013-1211-9","volume":"127","author":"KA Josephs","year":"2014","unstructured":"Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW (2014) Staging TDP-43 pathology in Alzheimer\u2019s disease. Acta Neuropathol 127(3):441\u2013450","journal-title":"Acta Neuropathol"},{"issue":"6","key":"9364_CR21","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1093\/brain\/awz099","volume":"142","author":"PT Nelson","year":"2019","unstructured":"Nelson PT, Dickson DW, Trojanowski JQ et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503\u20131527","journal-title":"Brain"},{"issue":"9","key":"9364_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41582-023-00846-7","volume":"19","author":"S Nag","year":"2023","unstructured":"Nag S, Schneider JA (2023) Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases. Nat Rev Neurol 19(9):525\u2013541","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"9364_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00401-024-02728-8","volume":"147","author":"DC Woodworth","year":"2024","unstructured":"Woodworth DC, Nguyen KM, Sordo L, Scambray KA, Head E, Kawas CH, Corrada MM, Nelson PT, Sajjadi SA (2024) Comprehensive assessment of TDP-43 neuropathology data in the National Alzheimer\u2019s Coordinating Center database. Acta Neuropathol 147(1):103","journal-title":"Acta Neuropathol"},{"issue":"4","key":"9364_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1021\/acs.biochem.9b01087","volume":"59","author":"T Tripathi","year":"2020","unstructured":"Tripathi T, Khan H (2020) Direct interaction between the \u03b2-amyloid core and tau facilitates cross-seeding: a novel target for therapeutic intervention. Biochemistry 59(4):341\u2013342","journal-title":"Biochemistry"},{"issue":"1","key":"9364_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/nm.4443","volume":"24","author":"Z He","year":"2018","unstructured":"He Z, Guo JL, McBride JD et al (2018) Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24(1):29\u201338","journal-title":"Nat Med"},{"issue":"10","key":"9364_CR26","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1093\/brain\/awac171","volume":"145","author":"L Pan","year":"2022","unstructured":"Pan L, Li C, Meng L et al (2022) Tau accelerates alpha-synuclein aggregation and spreading in Parkinson\u2019s disease. Brain 145(10):3454\u20133471","journal-title":"Brain"},{"issue":"2","key":"9364_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuron.2019.10.010","volume":"105","author":"F Bassil","year":"2020","unstructured":"Bassil F, Brown HJ, Pattabhiraman S et al (2020) Amyloid-beta (A\u03b2) plaques promote seeding and spreading of alpha-synuclein and tau in a mouse model of Lewy body disorders with A\u03b2 pathology. Neuron 105(2):260-275.e6","journal-title":"Neuron"},{"key":"9364_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2022.102270","volume":"214","author":"U Sengupta","year":"2022","unstructured":"Sengupta U, Kayed R (2022) Amyloid \u03b2, tau, and \u03b1-synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol 214:102270","journal-title":"Prog Neurobiol"},{"issue":"10","key":"9364_CR29","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21(10):1341\u20131349","journal-title":"Nat Neurosci"},{"issue":"11","key":"9364_CR30","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai H, Ikezu S, Tsunoda S et al (2015) Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 18(11):1584\u20131593","journal-title":"Nat Neurosci"},{"issue":"4","key":"9364_CR31","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1002\/alz.13658","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Toja A, Paolini Paoletti F et al (2024) Investigating alpha-synuclein co-pathology in Alzheimer\u2019s disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay. Alzheimers Dement 20(4):2444\u20132452","journal-title":"Alzheimers Dement"},{"issue":"6","key":"9364_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrn3961","volume":"16","author":"FM Menzies","year":"2015","unstructured":"Menzies FM, Fleming A, Rubinsztein DC (2015) Compromised autophagy and neurodegenerative diseases. Nat Rev Neurosci 16(6):345\u2013357","journal-title":"Nat Rev Neurosci"},{"issue":"8","key":"9364_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","volume":"13","author":"C Hetz","year":"2017","unstructured":"Hetz C, Saxena S (2017) ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol 13(8):477\u2013491","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"9364_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-019-0228-7","volume":"15","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol 15(9):501\u2013518","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"9364_CR35","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A et al (2017) A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169(7):1276-1290.e17","journal-title":"Cell"},{"issue":"1","key":"9364_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s41420-025-02538-1","volume":"11","author":"B Zhu","year":"2025","unstructured":"Zhu B, Feng J, Liang X, Fu Z, Liao M, Deng T et al (2025) TREM2 deficiency exacerbates cognitive impairment by aggravating \u03b1-Synuclein-induced lysosomal dysfunction in Parkinson\u2019s disease. Cell Death Discov 11(1):243","journal-title":"Cell Death Discov"},{"issue":"1","key":"9364_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC (2022) ApoE in Alzheimer\u2019s disease: pathophysiology and targeting strategies. Mol Neurodegener 17(1):72","journal-title":"Mol Neurodegener"},{"issue":"17","key":"9364_CR38","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N Engl J Med 361(17):1651\u20131661","journal-title":"N Engl J Med"},{"issue":"2","key":"9364_CR39","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.neuron.2017.02.042","volume":"94","author":"JD Ulrich","year":"2017","unstructured":"Ulrich JD, Ulland TK, Colonna M, Holtzman DM (2017) Elucidating the role of TREM2 in Alzheimer\u2019s disease. Neuron 94(2):237\u2013248","journal-title":"Neuron"},{"issue":"3","key":"9364_CR40","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1016\/S2666-7568(23)00022-3","volume":"4","author":"CK Suemoto","year":"2023","unstructured":"Suemoto CK, Leite REP (2023) Autopsy studies are key to identifying dementia cause. Lancet Healthy Longev 4(3):e94\u2013e95","journal-title":"Lancet Healthy Longev"},{"issue":"9","key":"9364_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-014-0082-1","volume":"6","author":"J Rahimi","year":"2014","unstructured":"Rahimi J, Kovacs GG (2014) Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther 6(9):82","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"9364_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2174\/156720512801322663","volume":"9","author":"DA Bennett","year":"2012","unstructured":"Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS (2012) Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 9(6):646\u2013663","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"9364_CR43","doi-asserted-by":"publisher","first-page":"e12189","DOI":"10.1002\/dad2.12189","volume":"13","author":"A Chatterjee","year":"2021","unstructured":"Chatterjee A, Hirsch-Reinshagen V, Moussavi SA, Ducharme B, Mackenzie IR, Hsiung GR (2021) Clinico-pathological comparison of patients with autopsy-confirmed Alzheimer\u2019s disease, dementia with Lewy bodies, and mixed pathology. Alzheimers Dement (Amst) 13(1):e12189","journal-title":"Alzheimers Dement (Amst)"},{"issue":"4","key":"9364_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/alzrt274","volume":"6","author":"PC Donaghy","year":"2014","unstructured":"Donaghy PC, McKeith IG (2014) The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis. Alzheimers Res Ther 6(4):46","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"9364_CR45","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jalz.2016.09.015","volume":"13","author":"WD Brenowitz","year":"2017","unstructured":"Brenowitz WD, Hubbard RA, Keene CD et al (2017) Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. Alzheimers Dement 13(6):654\u2013662","journal-title":"Alzheimers Dement"},{"issue":"1","key":"9364_CR46","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/jnen\/nlad098","volume":"83","author":"S Hiya","year":"2024","unstructured":"Hiya S, Maldonado-D\u00edaz C, Walker JM, Richardson TE (2024) Cognitive symptoms progress with limbic-predominant age-related TDP-43 encephalopathy stage and co-occurrence with Alzheimer disease. J Neuropathol Exp Neurol 83(1):2\u201310","journal-title":"J Neuropathol Exp Neurol"},{"issue":"1","key":"9364_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321","journal-title":"N Engl J Med"},{"key":"9364_CR48","unstructured":"Eisai Co., Ltd. New clinical data demonstrates three years of continuous treatment with LEQEMBI continues to significantly benefit early Alzheimer's disease patients. https:\/\/media-us.eisai.com\/2024-07-30-New-Clinical-Data-Demonstrates-Three-Years-of-Continuous-Treatment-with-Dual-Acting-LEQEMBI-R-lecanemab-irmb-Continues-to-Significantly-Benefit-Early-Alzheimers-Disease-Patients-Presented-at-The-Alzheimers-Association-International-Conference-A.\u00a0Press release. July 30, 2024"},{"issue":"6","key":"9364_CR49","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527","journal-title":"JAMA"},{"key":"9364_CR50","unstructured":"National Institute on Aging (2023) mNIA statement on donanemab results: more Alzheimer's research progress. https:\/\/www.nia.nih.gov\/news\/nia-statement-donanemab-results-more-alzheimers-research-progress.\u00a0 Published July 17, 2023"},{"issue":"1","key":"9364_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S, Chalkias S, Barkhof F et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79(1):13\u201321","journal-title":"JAMA Neurol"},{"issue":"1","key":"9364_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/1673-5374.340409","volume":"18","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, Balducci C, Ippati S, Watling M (2023) Initial failures of anti-tau antibodies in Alzheimer\u2019s disease are reminiscent of the amyloid-\u03b2 story. Neural Regen Res 18(1):117\u2013118","journal-title":"Neural Regen Res"},{"issue":"12","key":"9364_CR53","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/s43587-023-00523-w","volume":"3","author":"M Shulman","year":"2023","unstructured":"Shulman M, Kong J, O\u2019Gorman J et al (2023) TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer\u2019s disease. Nat Aging 3(12):1591\u20131601","journal-title":"Nat Aging"},{"issue":"1","key":"9364_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-41382-0","volume":"13","author":"H Geerts","year":"2023","unstructured":"Geerts H, Bergeler S, Walker M, van der Graaf PH, Courade JP (2023) Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model. Sci Rep 13(1):14342","journal-title":"Sci Rep"},{"issue":"14","key":"9364_CR55","doi-asserted-by":"publisher","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","volume":"101","author":"C Monteiro","year":"2023","unstructured":"Monteiro C, Toth B, Brunstein F et al (2023) Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet. Neurology 101(14):e1391\u2013e1401","journal-title":"Neurology"},{"issue":"1","key":"9364_CR56","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","volume":"61","author":"GK Wilcock","year":"2018","unstructured":"Wilcock GK, Gauthier S, Frisoni GB et al (2018) Potential of low dose leuco-methylthioninium bis(hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s disease: cohort analysis as modified primary outcome in a phase III clinical trial. J Alzheimers Dis 61(1):435\u2013457","journal-title":"J Alzheimers Dis"},{"key":"9364_CR57","doi-asserted-by":"crossref","unstructured":"Price DL, Khan A, Angers R, Cardenas A, Prato MK, Bani M, Bonhaus DW, Citron M, Biere AL. (2023) In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson's disease. npj Parkinsons Dis. 9(1):114","DOI":"10.1038\/s41531-023-00552-7"},{"issue":"6","key":"9364_CR58","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","volume":"29","author":"CJ Mummery","year":"2023","unstructured":"Mummery CJ, B\u00f6rjesson-Hanson A, Blackburn DJ et al (2023) Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med 29(6):1437\u20131447","journal-title":"Nat Med"},{"key":"9364_CR59","unstructured":"Alnylam Pharmaceuticals. (2024) ALN-APP Phase 1 clinical data. Presented at: Alzheimer's Association International Conference, Philadelphia, PA. https:\/\/capella.alnylam.com\/2024\/07\/31\/mivelsiran-aaic-2024"},{"issue":"9","key":"9364_CR60","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1084\/jem.20172158","volume":"215","author":"H Martini-Stoica","year":"2018","unstructured":"Martini-Stoica H, Cole TA, Swartzlander DB et al (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215(9):2355\u20132377","journal-title":"J Exp Med"},{"key":"9364_CR61","unstructured":"Washington University School of Medicine. DIAN-TU Tau NexGen study. ClinicalTrials.gov identifier: NCT05269394. https:\/\/clinicaltrials.gov\/study\/NCT05269394"},{"issue":"1","key":"9364_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00872-7","volume":"20","author":"H Hering","year":"2025","unstructured":"Hering H, Bussiere T, Liu CC, Glajch KE, Weihofen A, Grogan J, Walsh DM (2025) A manifesto for Alzheimer\u2019s disease drug discovery in the era of disease-modifying therapies. Mol Neurodegener 20(1):88","journal-title":"Mol Neurodegener"},{"issue":"12","key":"9364_CR63","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL et al (2022) The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 18(12):2669\u20132686","journal-title":"Alzheimers Dement"},{"issue":"5","key":"9364_CR64","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41591-021-01309-6","volume":"27","author":"JW Vogel","year":"2021","unstructured":"Vogel JW, Young AL, Oxtoby NP et al (2021) Four distinct trajectories of tau deposition identified in Alzheimer\u2019s disease. Nat Med 27(5):871\u2013881","journal-title":"Nat Med"},{"issue":"2","key":"9364_CR65","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1152\/physrev.00031.2020","volume":"102","author":"MK Rasmussen","year":"2022","unstructured":"Rasmussen MK, Mestre H, Nedergaard M (2022) Fluid transport in the brain. Physiol Rev 102(2):1025\u20131151","journal-title":"Physiol Rev"},{"key":"9364_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.595532","volume":"11","author":"C Alquezar","year":"2020","unstructured":"Alquezar C, Arya S, Kao AW (2020) Tau post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol 11:595532","journal-title":"Front Neurol"},{"issue":"7706","key":"9364_CR67","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng C, Gathagan RJ, Covell DJ et al (2018) Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature 557(7706):558\u2013563","journal-title":"Nature"},{"issue":"8","key":"9364_CR68","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nm.3232","volume":"19","author":"RA Nixon","year":"2013","unstructured":"Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat Med 19(8):983\u2013997","journal-title":"Nat Med"},{"issue":"2","key":"9364_CR69","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1001\/jamaneurol.2013.600","volume":"70","author":"D Tsuang","year":"2013","unstructured":"Tsuang D, Leverenz JB, Lopez OL et al (2013) APOE \u03b54 increases risk for dementia in pure synucleinopathies. JAMA Neurol 70(2):223\u2013228","journal-title":"JAMA Neurol"},{"issue":"11","key":"9364_CR70","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1001\/jamaneurol.2014.1455","volume":"71","author":"IF Mata","year":"2014","unstructured":"Mata IF, Leverenz JB, Weintraub D et al (2014) APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol 71(11):1405\u20131412","journal-title":"JAMA Neurol"},{"issue":"9","key":"9364_CR71","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1474-4422(18)30251-5","volume":"17","author":"HS Yang","year":"2018","unstructured":"Yang HS, Yu L, White CC et al (2018) Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE \u03b54 haplotype status: a community-based cohort study. Lancet Neurol 17(9):773\u2013781","journal-title":"Lancet Neurol"},{"issue":"7673","key":"9364_CR72","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y, Yamada K, Liddelow SA et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549(7673):523\u2013527","journal-title":"Nature"},{"issue":"32","key":"9364_CR73","doi-asserted-by":"publisher","first-page":"10139","DOI":"10.1021\/bi00032a006","volume":"34","author":"A Iwai","year":"1995","unstructured":"Iwai A, Yoshimoto M, Masliah E, Saitoh T (1995) Non-A beta component of Alzheimer\u2019s disease amyloid (NAC) is amyloidogenic. Biochemistry 34(32):10139\u201310145","journal-title":"Biochemistry"},{"issue":"8","key":"9364_CR74","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1074\/jbc.M609532200","volume":"282","author":"S Sarkar","year":"2007","unstructured":"Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC (2007) Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 282(8):5641\u20135652","journal-title":"J Biol Chem"},{"issue":"17","key":"9364_CR75","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"J Bieschke","year":"2010","unstructured":"Bieschke J, Russ J, Friedrich RP et al (2010) EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A 107(17):7710\u20137715","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"9364_CR76","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.1074\/jbc.M404751200","volume":"280","author":"F Yang","year":"2005","unstructured":"Yang F, Lim GP, Begum AN et al (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280(7):5892\u20135901","journal-title":"J Biol Chem"},{"issue":"3","key":"9364_CR77","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","volume":"487","author":"G Forloni","year":"2001","unstructured":"Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M (2001) Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487(3):404\u2013407","journal-title":"FEBS Lett"},{"issue":"3","key":"9364_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001888","volume":"3","author":"A De Luigi","year":"2008","unstructured":"De Luigi A, Colombo L, Diomede L et al (2008) The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 3(3):e1888","journal-title":"PLoS ONE"},{"issue":"3","key":"9364_CR79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","volume":"17","author":"F Leng","year":"2021","unstructured":"Leng F, Edison P (2021) Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol 17(3):157\u2013172","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"9364_CR80","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh SH (2020) Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener 9(1):42","journal-title":"Transl Neurodegener"},{"issue":"3","key":"9364_CR81","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133\u2013150","journal-title":"Nat Rev Neurol"},{"issue":"10","key":"9364_CR82","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, Basile P, Prato MK et al (2022) Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov Disord 37(10):2045\u20132056","journal-title":"Mov Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09364-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09364-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:02:50Z","timestamp":1793674970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09364-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":82,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9364"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09364-y","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"764"}}